Facilitators and Barriers to Cancer Treatment Among Texas Residents

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07105046

Enrollment

120

Registered

2025-08-05

Start date

2026-01-31

Completion date

2028-12-31

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

This trial uses semi-structured interviews and focus groups to determine facilitators and barriers of receiving timely cancer treatment among multiple cancers, across multiple insurance types, throughout Texas

Detailed description

Primary Objectives: Aim 1: To comprehensively assess barriers to and facilitators of receiving timely cancer treatment, via in-depth telephone interviews among a purposive sample of Texas patients with Stage I-IV breast, colorectal, lung, and prostate cancer and diverse backgrounds. Aim 2: To generate consensus on barriers and facilitators, as well as their relative importance, via focus groups, among carefully selected Texas patients with Stage I-IV breast, colorectal, lung and prostate cancer and diverse backgrounds,

Interventions

OTHERInterviews

A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.

OTHERFocus Groups

45 to 60 minutes video conference

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Aims 1 and 2 In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Verbal consent will be obtained * Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study * Males and females; Age ≥ 18 years old * Documented diagnosis of breast, colorectal, lung, and prostate cancer patients, stage I-IV * Either English or Spanish-speaking

Exclusion criteria

Aims 1 and 2 An individual who meets any of the following criteria will be excluded from participation in this study: * Patients who are cognitively impaired * Pregnant women

Design outcomes

Primary

Measure	Time frame	Description
1. Safety and Adverse Events (AEs)	Through study completion; an average of 1 year	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Countries

United States

Contacts

CONTACTJohn Lin, MD

jlin11@mdanderson.org(832) 729-0382

PRINCIPAL_INVESTIGATORJohn Lin, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026